
|Videos|April 6, 2016
Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer
Author(s)Christina Baik, MD, MPH
Christina Baik, MD, MPH, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer.
Advertisement
Christina Baik, MD, MPH, assistant professor, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, University of Washington, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer. Baik says there was a recent trial comparing the two drugs head-to-head, and results from the trial should be available soon.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5










































